Clearmind Medicine Inc. has announced significant progress in its FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a proprietary, non-hallucinogenic, MEAI-based oral therapy developed for Alcohol Use Disorder (AUD). The company reported positive top-line safety and efficacy results from the trial's first cohort of six participants, with dosing conducted at Johns Hopkins University School of Medicine and Yale School of Medicine. Following an unblinded interim safety review, the independent Data and Safety Monitoring Board (DSMB) unanimously recommended that the trial proceed. Additionally, Clearmind has expanded its clinical network by initiating patient enrollment at Tel Aviv Sourasky Medical Center in Israel, joining other active sites in the multinational study. Results from the initial cohort have already been presented.